Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer.

[1]  F. Cardoso,et al.  Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Yihong Wang,et al.  Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer , 2016, BMC Cancer.

[3]  K. Jirström,et al.  S100A9 expressed in ER−PgR− breast cancers induces inflammatory cytokines and is associated with an impaired overall survival , 2015, British Journal of Cancer.

[4]  J. Forbes,et al.  Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials , 2015, The Lancet.

[5]  L. Vatten,et al.  Microvascular proliferation in luminal A and basal-like breast cancer subtypes , 2015, Journal of Clinical Pathology.

[6]  Xi Wei,et al.  Prognosis of invasive breast cancer after adjuvant therapy evaluated with VEGF microvessel density and microvascular imaging , 2015, Tumor Biology.

[7]  Molin Wang,et al.  Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  N. Harbeck,et al.  uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies , 2014, Breast Cancer Research.

[9]  D. Generali,et al.  Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use , 2014, Tumor Biology.

[10]  T. Goldmann,et al.  Optimized immunohistochemistry in combination with image analysis: a reliable alternative to quantitative ELISA determination of uPA and PAI-1 for routine risk group discrimination in breast cancer. , 2013, Breast.

[11]  N. Harbeck,et al.  A randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine versus capecitabine monotherapy in first-line HER2-negative metastatic breast cancer (MBC). , 2013 .

[12]  M. Lux,et al.  Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. , 2013, European journal of cancer.

[13]  Stefan Michiels,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Soonmyung Paik,et al.  Use of archived specimens in evaluation of prognostic and predictive biomarkers. , 2009, Journal of the National Cancer Institute.

[15]  H. Allgayer,et al.  Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact. , 2009, Histology and histopathology.

[16]  R. Greil,et al.  Endocrine therapy plus zoledronic acid in premenopausal breast cancer. , 2009, The New England journal of medicine.

[17]  H. Nielsen,et al.  National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. , 2008, Clinical chemistry.

[18]  P. Span,et al.  Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA. , 2008, International journal of molecular medicine.

[19]  R. Greil,et al.  Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. , 2007, Journal of the National Cancer Institute.

[20]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  B. Nielsen,et al.  Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor , 2007, International journal of cancer.

[22]  B. Nielsen,et al.  The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. , 2003, The American journal of pathology.

[23]  B. Nielsen,et al.  Urokinase Plasminogen Activator Is Localized in Stromal Cells in Ductal Breast Cancer , 2001, Laboratory Investigation.

[24]  E. Dublin,et al.  Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. , 2000, The American journal of pathology.

[25]  G. Nenci,et al.  Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor‐1 is associated with breast cancer progression: An immunohistochemical comparison of normal, benign, and malignant breast tissues , 1996, Cancer.

[26]  U. Göhring,et al.  Comparative prognostic value of Cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma. , 1996, Anticancer research.

[27]  J. Foekens,et al.  Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Duffy,et al.  Urokinase-type plasminogen activator and its inhibitor PAI-1 in breast cancer: studies at both protein and mRNA level. , 1991, Biochemical Society transactions.

[29]  L. Ramón,et al.  Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer. , 2007, Thrombosis research.

[30]  M. Schmitt,et al.  Monoclonal Antibodies Against Plasminogen Activators and Plasmin(ogen) , 1992 .